 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
on Renal Tubular Epithelial Cells by Blocking Smad2 Activation
*Department of Medicine, Baylor College of Medicine, Houston, Texas; Department of Medicine, The University of Hong Kong, Hong Kong; and Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia.
Correspondence to: Dr. Hui Y. Lan, Department of Medicine-Nephrology, Baylor College of Medicine, One Baylor Plaza, Alkek N520, Houston, TX 77030. Phone: 713-798-1303; Fax: 713-798-5010; E-mail: hlan{at}bcm.tmc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
(TGF-) is a potent mediator in renal fibrosis and that Smad proteins are critical intracellular mediators in TGF- signaling. It is here reported that TGF- mediates renal fibrogenesis in tubular epithelial cells (TEC) in association with the activation of Smad2 and that overexpression of Smad7 blocks this fibrotic process. Using a normal rat kidney tubular epithelial cell line (NRK52E), it was determined that TGF-1 induces Smad2 phosphorylation and nuclear localization in both a dose- and time-dependent manner. The activation of Smad2 was evident at 5 min (20%), peaked at 15 to 30 min (85%), and declined to baseline levels by 2 h (5 to 10%). This was associated with de novo expression of collagens I, III, and IV and the transformation of TEC into a "myofibroblast" phenotype with de novo expression of 
-smooth muscle actin (-SMA) and with the loss of E-cadherin (>50%). To investigate a negative regulatory role of Smad7 in renal fibrosis, the Smad 7 gene was stably transfected and its expression was tightly controlled by doxycycline into NRK52E cells. Overexpression of Smad7 induced by doxycycline results in marked inhibition of TGF-–induced Smad2 activation (90%
) with the prevention of collagen synthesis and myofibroblast transformation. Thus, Smad2 activation occurs in the fibrogenic response of TEC to TGF-, and this process is blocked by overexpression of Smad7. This indicates that Smad signaling is a key pathway of TGF-–mediated renal fibrosis and suggests that treatments targeting the inactivation of Smad2 by overexpression of Smad7 may provide a new therapeutic strategy for renal fibrosis. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
(TGF-) (2). It has been shown that TEC can express fibroblast specific protein–1 (FSP-1) (3). Furthermore, we have recently demonstrated that TEC are profibrotic cells capable of transdifferentiation into ECM-producing myofibroblasts (-smooth muscle actin [-SMA+]) and that they play an active role in the development of tubulointerstitial fibrosis (4).
TGF- is a secreted signaling molecule with fibrotic properties, and it regulates a diverse range of cellular responses, including proliferation, differentiation, migration and apoptosis (5,6). There is increasing evidence that TGF- is a key mediator of fibrosis in both experimental and human kidney diseases (5,6). This is clearly illustrated by the finding that renal fibrosis can be induced by the deliberate overexpression of TGF-1 within the normal kidney (7). TGF- stimulates ECM deposition by both increasing the synthesis of ECM proteins and by inducing the production of protease inhibitors, which block their degradation (6). In vitro, TGF- has been shown to stimulate collagen synthesis and induce expression of FSP-1 in cultured TEC (8). Most recently, we demonstrated that TGF- is able to induce normal TEC to transform into a myofibroblast phenotype (9). Tubular epithelial cells expressing a myofibroblast-like phenotype have also been identified in human glomerulonephritis with progressive tubulointerstitial fibrosis (10). These studies suggest that TGF- may play an important role in the pathogenesis of tubulointerstital fibrosis.
Recent studies have suggested a pivotal role of Smads as intracellular effector molecules of the TGF- family members (11,12). TGF- exerts its biologic effects by signaling through a heteromeric receptor complex of the type I and type II serine/threonine kinase receptors, TRI and TRII (11,12). In the absence of TGF-, TRI and TRII form a latent receptor complex. Upon TGF- binding, the receptors rotate relatively within the complex (11,12), resulting in phosphorylation of TRI by the constitutively active and autophosphorylated TRII and thereby activate TRI. The activated TRI then directly signals to downstream intracellular substrates, Smad2 and Smad3 (R-Smads). Activated R-Smads heteroligomerize with the common partner Smad4 (Co-Smad) and these complexes are translocated into the nucleus to regulate target gene expression. Activation of the TGF- signaling pathway can also result in the expression of inhibitory Smads (I-Smads), including Smad6 and Smad7. These inhibitory Smads appear to act by specifically inhibiting Smad2 and Smad3 phosphorylation by blocking their access to TRI (11,12).
The involvement of Smads in TGF-–mediated renal fibrosis has been demonstrated by the groups of Poncelet et al. (13,14) and Schiffer et al. (15), with the findings that Smads may play a role in TGF-–induced collagen matrix synthesis in human mesangial cells and podocyte apoptosis during glomerulosclerosis. In this study, we have examined the role of Smad signaling in the fibrogenic response of TEC (NRK52E) to TGF-. We report that TEC stimulated with TGF- caused activation of Smad2 (phosphorylation and nuclear localization) with the de novo expression of collagens I, III, and IV and the transformation of TEC into a "myofibroblast" phenotype (-SMA+) with the loss of E-cadherin. We also report that overexpression of Smad7 blocks Smad2 activation and prevents collagen synthesis and myofibroblast transformation. Thus, this study demonstrates the actual role for Smad signaling in regulating (Smad2) and counter-regulating (Smad7) tubular fibrogenesis in response to TGF-.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell Culture
The stable, Dox-regulated Smad7–expressing NRK52E cells were grown in a 5% CO2 atmosphere at 37°C in Dulbecco’s modified Eagle’s medium (Life Technologies BRL, Gaithersburg, MD) containing 0.5% fetal bovine serum, 60 µg/ml penicillin, and 100 µg/ml streptomycin in 6-well plastic plates or eight-chamber glass slides (Nunc, Naperville, CT). A recombinant human TGF-1 (R&D Systems, Minneapolis, MN) at concentrations of 0, 0.615, 1.25, 2.5, 5, and 10 ng/ml were added into the cell culture for periods of 0, 5, 15, 30, 60, and 120 min and 1, 3, and 5 d. To induce overexpression of Smad7, cells were treated with Dox at designated concentrations of 0, 0.125, 0.25, 0.5, 1, and 2 µg/ml for 24 h. TGF-1 was then added at the designated concentrations for periods as described above. At least four experiments were performed throughout the study.
Reverse Transcriptase–PCR Analyses
Total RNA was isolated using the High Pure RNA Isolation Kit according to the manufacturer’s instructions (Roche Molecular Biochemicals, Indianapolis, IN). Contaminated DNA was removed by treating the samples with RNAase-free DNAase I (Promega, Madison, WI). Reverse transcriptase–PCR (RT-PCR) was performed using a ThermoScrip RT-PCR Kit following the manufacturer’s instruction (Life Technologies BRL). The first-strand cDNA was synthesized by using oligonucleotide primers and M-MLV reverse transcriptase (Promega) before PCR amplification (35 cycles) using primers specific for mouse Smad2 (5'-GTTCAATCCAGCAAGGAGTAC-3' and 5'-CTCATGCGGTGCACATTC-3'), Smad7 (5'-CATACTGGGAGGAGAAGA-3' and 5'-CTGTTGAAGATGACCTCTAGCC-3'), rat collagen type I (5'-TGCCGTGACCTCAAGATGTG–3' and 5'-CACAAGCGTGCTGTAGGTGA-3'), collagen type III (5'-CTG GAC CAA AAG GTG ATG CTG-3' and 5'-TGC CAG GGA ATC CTC GAT GTC-3'), collagen type IV (5'-CTC AGG TCT CTG CTC AGA GCC-3' and 5'-CTG CGC TCC TCG TGG AGC AGA AG-3'), -SMA (5'-GAT CAC CAT CGG GAA TGA ACG C-3' and 5'-CTT AGA AGC ATT TGC GGT GGA C-3'), E-cadherin (5'-CTC AGT GTT TGC TCG GCG TTT GC-3' and 5'-GCT CTG GGT TGG ATT CAG AG-3'), and GAPDH (5'-TCC GCC CCT TCC GCT GAT G-3' and 5'-CAC GGA AGG CCA TGC CAG TGA-3'). All samples were subjected to RT-PCR for housekeeping gene GAPDH as a positive control and as an internal standard. Afterward, RT-PCR products were resolved on 1.5% agarose gels in 1x Tris-borate-EDTA (TBE) buffer, visualized by ethidium bromide, photographed using a gel 1000 ultraviolet documentation system (Bio-Rad, Hercules, CA), and analyzed by densitometry.
Western Blot Analyses
NRK52E cells grown in six-well plates with or without TGF-1 or Dox were analyzed by Western blotting as described previously (9). Cells were washed in phosophate-buffered saline (PBS) and then lysed in 1 ml of 1% Nonidet P-40, 25 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, pH 8.0, containing a 1:50 dilution of a protease inhibitor cocktail (P2714; Sigma, St. Louis, MO) for 30 min on ice. Samples were centrifuged at 14,000 g for 5 min to pellet cell debris. Samples (20 µg) were mixed with sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, boiled for 5 min, electrophoresed on a 10% SDS polyacrylamide gel, and electroblotted onto Hybond-ECL nitrocellulose membrane (Amersham International, Buckinghamshire, UK). The membrane was blocked in PBS containing 5% skimmed milk powder and 0.02% Tween 20. To detect phosphorylated Smad2 (p-Smad2), total Smad2 and Smad7, collagen types I, III, and IV protein synthesis, and tubular epithelial-myofibroblast transformation (TEMT) with the de novo expression of -SMA and the loss of E-cadherin, the membrane was incubated for 1 h with mouse monoclonal (mAb) to Smad2 (Transduction Laboratories, Lexington, KY) or polyclonal antibodies (Ab) to Smad7 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), p-Smad 2 (Upstate Biotechnology, Lake Placid, NY), rabbit polyclonal antibodies to collagen types I, III, and IV (Santa Cruz Biotechnology), mAb to -SMA (1A4, Sigma), and anti–E-cadherin antibody (Santa Cruz Biotechnology). After washing, the membrane was incubated with a 1:20,000 dilution of peroxidase-conjugated goat anti-mouse IgG or swine anti-rabbit IgG in PBS containing 1% normal goat serum and 1% fetal calf serum. The blot was then developed using the ECL detection kit (Amersham International) to produce a chemiluminescence signal, which was captured on x-ray film.
Immunocytochemical Analyses
NRK52E cells were cultured in eight-chamber glass slides in the presence or absence of TGF-1 or Dox as described above. Cells were analyzed for activation of Smad2 using the anti–p-Smad2 antibody. Briefly, cells were fixed in 2% paraformaldehyde and preincubated with 10% fetal calf serum and 10% normal sheep serum to block nonspecific binding. Cells were then incubated with the anti–p-Smad2 Ab or an irrelevant isotype control rabbit IgG at 4°C overnight. After inactivation of endogenous peroxidase, cells were incubated with peroxidase-conjugated goat anti-mouse IgG or swine anti-rabbit IgG and then by the mouse or rabbit peroxidase anti-peroxidase complexes. After being washed, slides were developed with diaminobenzidine to produce a brown color, and the cell nucleus was counterstained with hematoxylin.
Microwave-based two-color immunostaining was used to examine TGF-–induced TEC-myofibroblast transformation and the inhibition of this process by Dox-induced overexpression of m2-Smad7 (9,17). Briefly, after color developing with the anti–-SMA mAb as described above, cells were treated with 10 min of microwave oven heating in 10 mM sodium citrate (pH 6.0) at 2450 MHz and 800 watts of power to block antibody cross-reactivity and to facilitate antigen retrieval. Cells were then incubated with the anti-m2 mAb (IBI, Eastman Kodak Co.) or control mAb (73.5, which recognized human CD45R antigen) for 60 min and then with alkaline phosphatase-conjugated goat anti-mouse IgG and mouse alkaline phospatase anti-alkaline phosphatase complexes. Finally, sections were developed with Fast Blue BB Base (Sigma) and coverslipped in an aqueous mounting medium. All procedures were performed at room temperature.
Quantitative Analyses
For quantitative analyses of p-Smad2 transnuclear location, Smad7 expression, and -SMA, the percentage of positive cells in eight-chamber slides stained for various Abs as described above was determined by counting at least 1000 cells under high power (x400) in each well. All scoring was performed blind on coded slides.
Statistical Analyses
Data obtained from this study are expressed as the mean ± SD. Statistical analyses were performed using GraphPad Prism 3.0 (GraphPad Software, Inc. San Diego, CA). Differences in p-Smad2, Smad7, ECM, and E-cadherin expression were assessed by one-way ANOVA or by t test.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1 Induces Activation of Smad2 in Renal Tubular Epithelial Cells–induced Smad2 activation in TEC, NRK52E cells were cultured with the TGF-1 for periods of time and examined for Smad2 activation. As shown in Figure 1A, immunocytochemical analyses demonstrated that TGF-1 (10 ng/ml) induced a rapid transnuclear location of p-Smad2 in a time-dependent manner, being evident at 5 min (20%), peaking over 15 to 30 min (85%), and then declining to normal levels by 2 h (5 to 10%). Consistent with these observations, Western blot analyses showed that TGF-1–induced Smad2 phosphorylation in both a time-dependent and dose-dependent fashion (Figure 1B).
|
–Induced Smad2 Phosphorylation and Nuclear Localization signaling, particularly in R-Smad activation (11,12). To investigate the counter-regulating role of Smad7 on TGF-–induced Smad2 activation in renal TEC, we established a cell line in which the expression of Smad7 in NRK52E cells was tightly regulated by Dox. We first examined the ability of Dox to induce Smad7 expression. As shown in Figure 2A, cells cultured in the presence of Dox for 24 h exhibited a strong Smad7 expression in a dose-dependent manner, with maximal expression at 2 µg/ml. We then examined the counter-regulating role of Smad7 in the inhibition of TGF-–induced Smad2 activation. As demonstrated by Western blot analyses, TGF-–induced Smad2 phosphorylation was inhibited by the addition of Dox in both a time-dependent and dose-dependent fashion, with marked inhibition of Smad2 phosphorylation at a dose of 2 µg/ml of Dox (Figure 2, B and C). This inhibitory effect is on the activation (phosphorylation), because Dox-induced Smad7 overexpression did not alter Smad2 expression at both protein (unphosphorylated) and mRNA levels (Figure 2, D and E). Immunostaining also showed that inducing overexpression of Smad7 by the addition of Dox caused a marked inhibition of Smad2 transnuclear location in a dose-dependent manner (Figure 2F). These data demonstrate that overexpression of Smad7 is able to negatively regulate TGF-–induced Smad2 activation in NRK52E cells.
|
on Renal Tubular Epithelial Cells stimulates fibrotic transdifferentiation of renal tubular epithelial cells into myofibroblasts (9). We now examined whether this TGF-–induced fibrotic process is regulated by Smad signaling. Using a Dox-regulated Smad7–expressing NRK52E cells, TGF-1 (in the absence of Dox) induced NRK52E cells to transform into a myofibroblast phenotype as evidenced by de novo synthesis of -SMA mRNA (Figure 3A) and protein (Figure 3B), a myofibroblast marker, and by the loss of the epithelial marker, E-cadherin mRNA and protein, a molecule that plays a key role in maintaining the integrity of epithelial cells (Figure 3, A and B). Furthermore, TGF-1 also induced the synthesis of ECM mRNA (Figure 3A) and protein (Figure 3B) by TEC, including collagen types I, III, and IV in a dose-dependent manner. RT-PCR showed that a significant increase in -SMA and collagen (types I, III, and IV) mRNA expression was evident at day 1 (P < 0.001) and steadily increased with time, and this was associated with the loss of E-cadherin mRNA expression (Figure 4, A and C). We then examined whether TGF-–induced fibrotic effects on TEC can be blocked by Smad7. As shown in Figures 4, A(i) and C(i), and 5A, TGF- induced low levels of endogenous Smad7 mRNA and protein expression in a time-dependent manner, being significant at day 3. Strikingly, the addition of Dox for 24 h before the addition of TGF- (termed day 0) induced marked Smad7 mRNA and protein expression in a time-dependent and/or dose-dependent manner (Figures 4, B(i) and C(i), and 5A). When overexpression of Smad7 was induced, TGF-–induced TEC transdifferentiation into ECM-producing myofibroblasts was significantly inhibited. This was demonstrated by inhibition of de novo -SMA mRNA and protein synthesis, the maintenance of E-cadherin expression, and inhibition of collagen mRNA and protein synthesis (Figures 4, B and C, and 5). The suppressive effect of TGF-–induced TEC-myofibroblast transformation and ECM production by Smad7 was time-dependent (Figure 4, B and C) and dose-dependent (Figure 5). These results were further supported by two-color immunostaining in which cells expressing Smad7 (induced by Dox) did not express the myofibroblast marker (-SMA+), preventing TEC-myofibroblast transformation (Figure 6, A through C). Semiquantitative analyses showed that the number of Smad7-expressing cells inversely correlated with the number of -SMA+ cells (Figure 6D).
|
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
in renal fibrosis. Using this model, we have found that TGF- activates Smad2 in renal TEC in association with ECM production and myofibroblast transformation and that overexpression of Smad7 blocks this process.
TGF- has long been considered to play a pathogenic role in renal fibrosis. The recent discovery of the TGF- signaling pathway, Smads, allows us to delineate the exact mode of TGF- action in this process. It is well documented that TGF- binds to TRII, resulting in the activation of TRI, which causes the phosphorylation of specific Smad proteins, called R-Smads, including Smad2 and Smad3, that initiate TGF- signaling transduction (18–21). On the other hand, activated TRI also induces the activation of inhibitory Smad7 that function to antagonize TGF- signaling by preventing TGF- receptor–mediated phosphorylation of Smad2 and Smad3 (22,23) and by increasing ubiquitin-mediated degradation of the TGF- type I receptor itself (24). In this study, we found that the fibrotic effects of TGF- on renal TEC, in terms of collagen production and myofibroblast transformation, may signal through the activation of Smad2. Indeed, blockade of Smad2 activation by inducing overexpression of its inhibitor, Smad7, results in inhibition of TGF-–induced TEC-myofibroblast transformation and collagen production. The tight association between Smad2 activation and de novo synthesis of -SMA (a marker of myofibroblasts) and collagen types I, III, and IV mRNA and protein indicates that the phosphorylated Smad2 may act on the target genes to regulate TEC to become collagen-producing myofibroblasts at the transcriptional level when it is translocated into the nucleus. This is further demonstrated by the finding that overexpression of Smad7 inhibits TGF-–induced Smad2 phosphorylation and nuclear localization, subsequent TEC-myofibroblast transformation, and collagen matrix production. Thus, activation of Smad2 may be required for TGF-–induced fibrotic effects on TEC. This also implies that activation of Smad2 may be one intracellular mechanism by which TGF- mediates renal fibrosis. These observations are consistent with the recent finding that TGF- induces collagen matrix in human mesangial cells by a process involving the activation of Smad proteins (13,14).
It is also possible that the activation of Smad3, another R-Smad protein, may be required for TGF-–induced fibrotic process in TEC. Indeed, TGF- induced Smad3 nuclear localization was also evident in this study (data not shown). Activation of Smad3 has been shown to promote TGF-–induced 2(I) collagen gene expression by human mesangial cells, which is enhanced by Sp1 (14). There are some functional differences between Smad2 and Smad3. Smad3 is involved in activation of the Smad7 gene promoter (25), whereas Smad2 has a functional role in TGF-1-induced the matrix metalloproteinase MMP-2 (26). Smad3-deficient mice show accelerated wound healing and die from chronic inflammation (27,28) and colon carcinomas between 4 and 6 mo of age (29), whereas Smad2-deficient mice are embryonic lethal (30). However, the functional role of Smad3 in TGF-–induced TEC-myofibroblast transformation and collagen production by TEC remains to be defined.
Smad7 and Smad6 belong to an inhibitory subfamily of Smads that block both TGF- and bone morphogenetic protein signaling, whereas Smad6 is able to inhibit bone morphogenetic protein signaling and partially inhibit TGF- signaling (22,23,31,32). Endogenous Smad7 is rapidly induced by TGF- and, in turn, downregulates TGF- signaling through a negative feedback loop to prevent R-Smad from phosphorylation, an early step of TGF- signaling (11,12,31). Smad7 may act by competition for binding of R-Smad2/3 to TRI, thereby blocking Smad2 and Smad3 from interacting with the receptor after TGF- stimulation (11,12,31,33), or by increasing ubiquitin-mediated degradation of TGF- receptor (24). It has been shown that Smad7, but not Smad6, is a TGF-–induced attenuator of Smad2/3-mediated inhibition of embryonic morphogenesis (34,35). Overexpression of Smad7, but not Smad6, inhibits TGF-–induced heme oxygenase-1 by human TEC (36). Expression of Smad7 transgene also blocks Smad2 phosphorylation induced by bleomycin in mouse lung, and gene transfer of Smad7, but not Smad6, prevents bleomycin-induced lung fibrosis (37). In this study, we have investigated the negative regulatory role of Smad7 in the profibrotic effects of TGF- on renal TEC using an improved Tet–inducible system in which the expression of Smad7 is under the tight control of Dox. We found that TGF- induced endogenous Smad7 expression, but that the low grade of endogenous Smad7 expression was unable to overcome the fibrogenic effect of TGF- on renal TEC associated with the activation of R-Smads. We found, however, that inducing overexpression of Smad7 transgene by addition of Dox blocked the activation of Smad2 and prevented the TGF-–induced TEC-myofibroblast transformation and stimulation of collagen types I, III, and IV mRNA and protein synthesis. Thus, overexpression of Smad7 is able to alter the physiopathologic balance between R-Smads and I-Smads in TEC in response to TGF- and blocks TGF-–induced fibrosis.
Although inhibition of Smad2 and Smad3 may block TGF-–mediated fibrosis, recent studies in Smad2 and Smad3 knockout mice have demonstrated that absence of Smad2 and Smad3 may also impair the immune system and embryonic development (27–30). In contrast, overexpression of Smad7 may also cause cell death through apoptosis (15,38). Therefore, it is critical to maintain a physiologic balance between R-Smads and I-Smads when attempting to target TGF- signaling. In this study, the degree of expression of Smad7 could be controlled by varying the concentrations of Dox. These in vitro data implicate that it may be more safe and advantageous to use a Dox-regulated Smad7, rather than naked Smad7 gene alone, to prevent or treat renal fibrosis in vivo.
TGF- is a major mediator in renal fibrosis and acts to both regulate the transdifferentiation of TEC into myofibroblasts and to stimulate their synthesis of ECM proteins (4–10,39,40). In this study, we demonstrate that the fibrogenic effect of TGF- in TEC involves activation of Smad2 and that overexpression of Smad7 can block Smad2 activation and the fibrogenic process. Thus, this study demonstrates the complex interplay between R-Smads (Smad2) and I-Smads (Smad7) in TGF-–induced tubular fibrogenesis.
|
Acknowledgments |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 56: 1455–1467, 1999[CrossRef][Medline]
signaling. Curr Opin Genet Dev 8: 103–111, 1998[CrossRef][Medline]
-mediated signaling pathways. J Biol Chem 274: 32258–32264, 1999 receptor and functions as an antagonist of TGF- signaling. Cell 89: 1165–1173, 1997[CrossRef][Medline]
. EMBO J 18: 1280–1291, 1999[CrossRef][Medline]
1 Induces Nuclear Export of Inhibitory Smad7. J Biol Chem 44: 29195–29201, 1998
This article has been cited by other articles:
 |
|
 |
|
  K. Vaahtomeri, E. Ventela, K. Laajanen, P. Katajisto, P.-J. Wipff, B. Hinz, T. Vallenius, M. Tiainen, and T. P. Makela Lkb1 is required for TGF{beta}-mediated myofibroblast differentiation J. Cell Sci., November 1, 2008; 121(21): 3531 - 3540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-Y. Chun, P. N. Chander, J.-W. Kim, J. H. Pratt, and C. T. Stier Jr. Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E305 - E312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. R. Huang, A. C. K. Chung, X. J. Wang, K. N. Lai, and H. Y. Lan Mice overexpressing latent TGF-{beta}1 are protected against renal fibrosis in obstructive kidney disease Am J Physiol Renal Physiol, July 1, 2008; 295(1): F118 - F127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Sullivan Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1220 - R1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. R. Huang, A. C.K. Chung, L. Zhou, X. J. Wang, and H. Y. Lan Latent TGF-{beta}1 Protects Against Crescentic Glomerulonephritis J. Am. Soc. Nephrol., February 1, 2008; 19(2): 233 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Guo, J. C.K. Leung, M. F. Lam, L. Y.Y. Chan, A. W.L. Tsang, H. Y. Lan, and K. N. Lai Smad7 Transgene Attenuates Peritoneal Fibrosis in Uremic Rats Treated with Peritoneal Dialysis J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2689 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, L. Soltero, P. Zhang, X. R. Huang, H. Y. Lan, and H. J. Adrogue Renal inflammation is modulated by potassium in chronic kidney disease: possible role of Smad7 Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1123 - F1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, C. Dai, C. Wu, and Y. Liu PINCH-1 Promotes Tubular Epithelial-to-Mesenchymal Transition by Interacting with Integrin-Linked Kinase J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2534 - 2543. [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Park, M.-J. Choi, I.-K. Song, S.-Y. Choi, J.-O. Nam, C.-D. Kim, B.-H. Lee, R.-W. Park, K. M. Park, Y.-J. Kim, et al. Erythropoietin Decreases Renal Fibrosis in Mice with Ureteral Obstruction: Role of Inhibiting TGF-beta-Induced Epithelial-to-Mesenchymal Transition J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1497 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Gonzalez, F. Le Bellego, and M. S. Ludwig Imbalance of Receptor-Regulated and Inhibitory Smads in Lung Fibroblasts from Bleomycin-Exposed Rats Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 206 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fu, F. Liu, S. Su, W. Wang, X. R. Huang, M. L. Entman, R. J. Schwartz, L. Wei, and H. Y. Lan Signaling Mechanism of Renal Fibrosis in Unilateral Ureteral Obstructive Kidney Disease in ROCK1 Knockout Mice J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3105 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abbate, C. Zoja, and G. Remuzzi How Does Proteinuria Cause Progressive Renal Damage? J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2974 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E N Blaney Davidson, E L Vitters, P M van der Kraan, and W B van den Berg Expression of transforming growth factor-{beta} (TGF{beta}) and the TGF{beta} signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation Ann Rheum Dis, November 1, 2006; 65(11): 1414 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Padda, A. Wamsley-Davis, M. C. Gustin, R. Ross, C. Yu, and D. Sheikh-Hamad MEKK3-mediated signaling to p38 kinase and TonE in hypertonically stressed kidney cells Am J Physiol Renal Physiol, October 1, 2006; 291(4): F874 - F881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruiz-Ortega, M. Ruperez, V. Esteban, J. Rodriguez-Vita, E. Sanchez-Lopez, G. Carvajal, and J. Egido Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases Nephrol. Dial. Transplant., January 1, 2006; 21(1): 16 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rodriguez-Vita, E. Sanchez-Lopez, V. Esteban, M. Ruperez, J. Egido, and M. Ruiz-Ortega Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-{beta}-Independent Mechanism Circulation, May 17, 2005; 111(19): 2509 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, X. R. Huang, A. G. Li, F. Liu, J.-H. Li, L. D. Truong, X. J. Wang, and H. Y. Lan Signaling Mechanism of TGF-{beta}1 in Prevention of Renal Inflammation: Role of Smad7 J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1371 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 |
